Markets on edge as tariff deadline looms & the future of vaccine development in the FDA 3/31/25

31 Mar 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Notes: CNBC's "Fast Money" Episode Summary

Episode Details

  • Title: Markets on edge as tariff deadline looms & the future of vaccine development in the FDA
  • Air Date: 03/31/2025
  • Hosts: Melissa Lee with traders Tim Seymour, Karen Fineman, Dan Nathan, and Dai Adami.
  • Overview: The episode discusses market reactions to upcoming tariffs, the resignation of a key FDA official, and its implications on the biotech sector, among other topics.

---

Key Topics Discussed

  1. Market Overview
  2. Quarterly Performance:
  3. The S&P and Dow posted minor gains but ended the quarter with overall losses.
  4. Major indices (S&P, Nasdaq) experienced their worst first quarter since 2020.
  • Tariffs Impact:
  • A looming 25% tariff on certain imports is set to be enacted, heightening market volatility.
  • Uncertainty regarding the effects of these tariffs is weighing heavily on consumer confidence, particularly affecting discretionary sectors like tech and communication services, which have seen the worst declines.
  • Market Sentiment:
  • Discussion on the lack of clarity in the market moving forward.
  • Concerns that the upcoming tariff deadline will not resolve uncertainties but rather initiate further volatility.
  • A potential bounce from the 5,500 S&P level was mentioned, but with caution about future declines.
  1. Biotech Sector Concerns
  2. FDA Resignation:
  3. Peter Marks, head of the FDA vaccine division, resigned, leading to concerns about future drug development.
  4. The resignation is viewed as a protest against political interference from Secretary RFK Jr.
  5. Potential brain drain at the FDA could hinder the approval process for novel therapies, impacting the biotech sector negatively.
  • Implications for Drug Development:
  • The discussion highlighted that the FDA’s ability to expedite drug approvals could be compromised.
  • Scientists may seek "scientific asylum" in more stable environments outside the U.S., affecting innovation.
  1. Investment Strategies
  2. Current Trends:
  3. Defensive sectors like healthcare and staples have been performing well, while discretionary stocks struggle.
  4. Overview of specific stocks, such as Walmart and Apple, indicating a trend towards defensive investments amidst market instability.
  • Concerns About Technology Stocks:
  • Analysts noted that tech stocks, including Nvidia, may face downward pressure due to overcapacity and waning demand.
  • Discussion surrounding Google’s competitive position in AI and search markets, with comparisons drawn to the decline of Kodak.
  1. Economic Projections
  2. Federal Reserve's Position:
  3. Insights from Richmond Fed President Tom Barkin emphasized uncertainty regarding rate cuts amidst inflation concerns.
  4. Expectations around economic growth, with projected inflation remaining around 3%, complicating monetary policy decisions.
  1. Gold Market Insights
  2. Gold prices reached all-time highs, with discussions regarding its continued upward trend and the potential for further gains.

---

Key Takeaways

  • Market Volatility: The impending tariffs are creating significant uncertainty, and traders are advised to brace for continued volatility.
  • FDA Dynamics: The resignation of a key FDA official could slow down drug development, raising concerns for the biotech sector.
  • Defensive Investments: Shifting focus to defensive sectors might provide some stability in an unpredictable market.
  • Tech Sector Challenges: The technology sector faces headwinds due to overcapacity and competition from emerging AI solutions, affecting stock valuations.
  • Economic Indicators: Investors are closely monitoring inflation rates and Fed policies, as these will inform future market directions.

---

Conclusion The episode of "Fast Money" provided an in-depth analysis of the current market landscape, addressing critical issues such as tariffs, the state of biotech under FDA changes, and strategic investment approaches in a shifting economic environment. Continued vigilance and adaptability in trading strategies were emphasized as essential for navigating the unfolding market scenarios.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:03Live from the Nasdaq MarketSite in the heart of New York City's Times Square. This is Fast Money. Here's what's on tap tonight. Three months to forget from tech to airlines to housing and beyond. Stocks finishing Q1 in the red and with tariffs set to take hold this week. Do traders need to brace for some of the same? Plus, biotech blues, a key FDA official, resigning in protest over RK Jr.'s views on immunizations and vaccines. The sector falling on fears that politics will trump medical science. Should investors worry? We'll debate that. And later, the crumble of core weave shares continues. Gold hits another all-time high.

0:35Can it keep climbing? And we will break down why one tech analyst is mentioning Google and Eastman Kodak in the same sentence. Yikes. Ouch. I'm Melissa Lee. Coming to you live from CEO of B at the NASDAQ. On the desk tonight, Tim Seymour, Karen Feinemann, Dan Nathan, and Dai Adami. And we start off with a countdown to so-called Liberation Day, Wednesday, April 2nd, when a 25 % tariff on autos and imports from any country that buys oil from Venezuela go into effect. We're also expecting announcements of reciprocal tariffs, Markets on edge as the date approaches. While the S &P and Dow both managed to post solid gains today, all three major indices are sharply lower so far this year.

1:11The S &P and Nasdaq both notching their worst first quarter since 2020. Uncertainty around the impact of tariffs on the economy weighing particularly hard on the consumer. Discretionary names the biggest drag on the markets this year, followed by tech and communication services. Meanwhile, defense has been the best offense with energy, health care and staples leading the pack in 2025. But if we get clarity on trade in the coming days, could that allow markets to put in a bottom, start to rally? Or is there more pain and volatility to come? What I heard today in terms of the conversation is there is no clearing event.

1:44April 2nd will come and go, and there will not be clarity still. Yeah, I agree with that. And I still think the path of least resistance is lower. I think the good news, and this is something that Tim said on the call today, that 5 ,500 level S &P, which is where we traded down to on March 13th and bounced from, which is where we traded down to today and bounced from. That seems to be, at least in the short term, sort of this administration's short term put on the downside. We'll see if that holds. So today's bounce, I guess, in terms of that level, in terms of quarter end, I guess it made sense.

2:13But I don't think you're going to get the clarity that the market needs in order to sort of grind higher again. I think it's going to stall out pretty quickly. I agree with that. I mean, I've looked last night at the futures. I saw down 50 handles. I'm like, all right, well, this is not going to be great. But you know that Friday closed. Friday was just an awful day. So that wasn't surprising. Where we ended up was actually a little bit surprising to me for the reasons you said. And you said, I don't think there's any clarity that's going to come out of that. I think that it will just be the beginning of more uncertainty, right?

2:43The tit for tat. We don't know where it'll end up. That's the part that sort of confuses me. Even if one accepts tariffs. Let's just say we think, OK, we understand why we want to do that. I'm not sure how the methodology is helpful to business confidence. It seems to be very damaging, right? So I don't really get that, which makes me think that the policies could change, right? It's not a lot of time before we get there. You'd think that they would know where it is already, but I think it could end up being in flux to the very end. Yeah, I'll echo that. I'll just say that I think today, you know, the 2.4 % off the bottom rallied at the close.

3:21I mean, that's a massive move. And some of this is quarter end. Some of this is also just sentiment. Look, sentiment this morning felt about as bad as I felt it in a while, even though there wasn't this clearing event. There wasn't really an event. And I think that's something to be said. I think it does set up for another one of these rallies. The problem often that we've had when we've had these periods of market downdraft is that earnings seasons come along and you've been able to focus on fundamentals. But we know this is going to be an earnings season where I actually think the numbers are going to be better than people are probably pricing in.

3:49but there's going to be zero about the guide that's going to be helpful. There's going to be a C-suite, almost every sector, pointing out the uncertainty that we're talking about relative to their daily life. So I think that's part of where we go. I would get back to today's tape where stuff that's defensive, whether that's an Altria, whether that's an AT &T, those had huge days. But you also, it was strange. Defense won, but also those oversold stocks won. And I think you could see some stocks back in the soup tomorrow. Yeah, and there's defense that's coming back into the mix, too. Look at Walmart closed up 3 % today.

4:20I thought Apple was really interesting because, again, if you go back to the playbook from 2018, Apple iPhones got an exclusion from some of these. And when I think about this, the sort of clarity that we might get over the next couple of weeks or so is like what products, what companies are going to be carved out of some of these sorts of tariffs as we think about the ones at least with our allies, which are our biggest trading partners, Canada, Mexico. And maybe they're kind of dropping a little bit by the wayside. And, you know, listen, I think the guide, like you said, is really important.

4:50And we can just go back a few weeks to the end of earnings season. What did we hear from Walmart? What did we hear from Costco? We heard about a consumer that they can't exactly put their finger on. Well, then you'd say to me, all right, well, why was Walmart today? What do you say, Guy? What's their little logo? Everyday low prices. Everyday low prices. So we've been talking about this trade down for like two years or so. So, again, there's going to be pockets of opportunities. Maybe it's sectors. Did you see like Pharma today? XLV had a nice rally back, that sort of thing. And so, you know, like as the silver lining guy on the desk, I just think there's opportunities here when we get down 10 percent or so that, you know, on an individual basis or on a second.

5:23An additional 10 percent from here. Well, I don't know. No, I mean, we're down 10 percent. I do think it's interesting that, you know, we're still looking at S &P that's down a little less than 5 percent of the year. The Nasdaq's down about 10 and a half percent or so. Not a disaster. Can I ask silver lining a question? You're in charge. OK, so so NVIDIA is trading around 22 times forward. And even before we knew about their AI exposure, really, this was a stock that generally traded at 40 times. At 22 times, you're pretty buffered. In other words, this isn't a stock that's necessarily priced to have the kind of growth that it's had.

5:53Do you think that that's interesting? And it's not rhetorical. It's truly not. Well, I'll just say this. We've been talking about this for a year and maybe a bit early. We're talking about the overbill, the overcapacity, the double ordering because of export bans. It goes on and on. Now all I do is read stories and very reputable, you know, kind of print stuff, I guess, digital now. They're just talking about this overcapacity bill. They're talking about pricing coming down dramatically for the compute. There's going to be pricing pressure, not because there's competition for NVIDIA, because there's not the demand, right?

6:22And there was this overbuild and this overdemand, like, you know, the last six months. That's here. That's happening. That's why that stock is trading at 22 times. That's why Broadcom, which was really late to the party late last year after they gave this guidance for custom silicon. Remember this in mid-December? The stock moved up. Yeah, it's down 38 % from that point. That's how it made it into Karen's fateful eight because it got over that trillion-dollar market cap. I didn't know she had her own. And since then, it's been down about 35%. It's barely seen an uptick in the last few weeks since it's reported.

6:49So that trade is done. The fever is broken. The hyperscalers, I don't think they come back anytime soon. So you guys better find some new leadership, I mean, you know, to kind of take this thing back towards those prior highs. OK, so you're back to being the number. There's no silver lining. Everything's in its place now. But Dan, as the silver lining's got, you did bring up a good point in terms of like peak pessimism about tariffs being priced into the market. And so over the next couple of weeks with carve outs, exemptions, et cetera, the upside, there could be upside that we are not anticipating in terms of the tariff situation.

7:19There could be upside. But one thing it tells me there is still pain to go is the VIX. The VIX will not stay around here. Right. We're going to see it higher before we see it lower. And so this is sort of no man's land. And I don't think it just drifts down. I think we start to. I'm with Karen on that. But if you think the only reason the market is sold off is because of tariffs and you think there's potential for them to acquiesce in some way and do something that's going to calm the markets. And yes, but I think tariffs is just part of the reason the market's going lower. There are other things that they have no control of, not least of which is slowing economy, which, you know, maybe they're sort of helping that along.

7:55but it's clearly been in place for a lot of time before this, I believe, as well. I don't think we've seen the kind of labor weakness that would warrant real concern about recession yet. I think there's some dynamics with the services part of the economy that have been very mixed. But I'm going to agree with that. I'm going to say I look at airlines and I look at some of the discretionary spend. These are trades that were under pressure on a combination of cyclicality in their core business, also in pent-up demand that was more than met, more than satiated. And we've seen this. And you can't tell me that the move lower in some of these discretionary names, we talk about them all the time, so I won't mention the names.

8:31You know them. It's not about tariffs. It wasn't about tariffs. I do think there's a part of this marketplace that was weak and vulnerable. All right. Meanwhile, our Steve Leisman sat down with the Richmond Fed President Tom Barkin this afternoon. He joins us now with all the headlines. And all the clarity that a Fed president can give these days. Unfortunately, Tom Barkin mostly emphasizing the uncertainty over policymaking, given the uncertainty over fiscal policy, which y 'all are just talking about. But he also suggests it's perhaps not wise for markets to be certain about rate cuts this year.

9:03To cut rates, you'd have to get confidence on inflation. You'd have to get confidence that inflation is settling. You could get that confidence because it actually continues to settle. You could get that confidence because the economy is in such tough shape that you feel that whatever downturn you have will also settle inflation. OK, y 'all can put these numbers in your pipe and trade them. The CNBC rapid update averaging the outlook for 14 Wall Street economists sees inflation remaining stuck near 3 percent for most of this year, which would, I think, make it tough for the Fed to cut. Rapid update also showed expected growth just 0.3 percent this quarter before rising gradually to 2 percent by year.

9:42And Barkin said he would be watching carefully the desire of importers to pass along the tariffs, keep their margins high and the unwillingness of consumers to pay more. Guys, we're not even at the right point of uncertainty here. The point of uncertainty that we sort of look for is not what the policy is going to be, but it's the effects of the policy. So we can't even get to that place where we could debate what are the tariffs going to be and then what's the inflationary impact. You guys all have to do margin calculations, right? Who's going to kick the hit on the margin? Who's going to pass along?

10:14Who has pricing power? Who doesn't? Those are the things that's going to make Tim right or wrong about the earnings numbers. And the things that are not modelable, the impact on the consumer. I mean, you can put in various tariff rates on various companies and try and turn that out, but you can't do that for the consumer necessarily in terms of the hit to their psychology and their hit to their intended spending. Tom Barkin has actually been, I think, one of the smartest guys on the Fed about this issue because he comes out, not from an economic theory point of view, but really a business point of view.

10:41And it's about the kind of culture of raising prices. He points out the last time we did this in 2018, they would laugh at you if you said here's higher prices. Now, post the pandemic, when there was this round of raising prices, you know, it's a different situation where the psychology is out there that business will try to get it those prices along. Now, you also have the situation where several years on, consumers are sick and tired of these higher prices. So he called of the kind of immovable object meeting the unstoppable force, you know. So that's kind of where we're at. And nobody knows how all this shakes out.

11:15How does he view the employment picture as it relates to whatever's going on in the economy in general, but tariffs specifically? I can do a little Socratic reasoning with you guys at the table here. All right. Go for it. If you're a company and you can't pass along your tariff increases and you're cutting into your margin, what are you doing? Firing people. There you go. Nice job. That's exactly what Barkin said is going to happen. You cut the margins, you're going to find them. If you're able to pass them along, then you have, okay, the other side of that, which is a worrisome side of it, is you have people asking for higher wages.

11:52You could have a wage price spiral. Or all of this could work out just fine. I'm waiting for somebody to send me the report that says, Steve, everything's going to work out just fine. Let me just throw one maybe silver lining in there. Good. I'll take one. Productivity increases. OK, so we have experienced a pretty nice run of productivity over the past several years. I think it results from the pandemic and right sizing people getting into the best possible job. I think work from home was a piece of it. We could argue about that. But the trouble you have is that tariffs. What's the right word?

12:26I'm going to make one up here. De-optimize the supply chain. And most people who try to figure out the impact on this, They say it's a productivity killer. Now, you still have AI. You still have all this other stuff. Now, it's going to stop that. I don't think AI is even in the productivity numbers at all yet. I think we're still getting pandemic business process productivity, if nothing else. But when you have to look, what's Mary Barr doing right now? Is she thinking about the next car? Is she thinking about how to, you know, make GM more profitable? Or is she trying to figure out where my seatbelts are coming from?

13:04And how much am I going to pay for them? So I think there's a de-optimization. Can I use that word? You did. I would have sub-optimized. Sub-optimized. That's fine. No, but actually sub-optimized means less optimization. De-optimized means you're going in the other direction. I think you are going in the other direction. Yeah. Do you think the Fed is trying to manage the message of this? When we were both on Squawk Walks a couple of weeks ago with Austin Goolsbee. Yeah. He mentioned the S word, stagflation word. We didn't bring it up in that conversation. But it feels like they're moving. I'm not saying that they're embracing that scenario at all, but they're sort of acknowledging that that is a scenario on the table.

13:41There's no doubt you look at I was just having a conversation. I think the Fed's forecast today would be different from the one when they just came out with. Yeah, we know a little bit more about the extent of the tariffs. We've had a lot more research done on this. Somebody did one that said 150 years of tariffs show unavoidably or incontrovertibly that it reduces growth. So I think they would have a more stagflationary forecast now. I think the Fed has been more open about talking about this than they were before. I still think they prefer that none of this was happening. Ex-Fed members are saying it.

14:19I mean, Robert Kaplan used it on Friday, and he's not afraid to say stagflation. Look at Muslim from Kansas City. You know, the New Kansas City, he's saying, sorry, St. Louis, he's going to have an incident here. But the St. Louis Fed, he said, look, if this thing comes out a certain way, we could be hiking rates. He's the one guy who said it. I'll bet it's on some other people's minds. Yeah, I want to make one point. You just talked about the car stuff. What do they have to do? You have to fire people. There was an article in the Wall Street Journal. I don't know if you guys saw it today. In the A section, it was about Harley Davidson.

14:47They're in Milwaukee. OK, so in 2018, the EU put a 25 percent tariff on their bikes. OK, they ate one hundred and sixty six million dollars to keep the pricing down of their bikes. What did they do, though? They moved some production to Thailand. So if you're talking about these tariffs as a dead bang winner to bring manufacturing back here, it just doesn't work that way. This is a great American company that actually doesn't buy into what the president's selling. Do you know I can tell you that there are CEOs right now who thought they were doing the right and patriotic thing and moved their production from China to Vietnam to Thailand to other places that are about to get slapped with tariffs?

15:27It's not a good thing. Steve, thank you. Pleasure. Nice to see you in person. Steve Leisman. Meantime, Evercore ISI sees market uncertainty peaking around the Wednesday tariff deadline. Julian Emanuel is the firm's senior managing director. You heard the conversation, Julian. But we're going to still be in a bull market. The trend is still going to be a bull market trend. Whatever pullback we see. That's our view. So a couple of things to think about. We've all seen that chart of trade policy uncertainty literally to highs that were unimaginable, certainly even when you think about the 2018, 2019 trade war.

16:03But I would suggest that, and Tim hit this earlier, the mood this morning and over the weekend talking with clients and talking with colleagues was as negative as I can remember going back to when Silicon Valley Bank blew up and we didn't know the Fed was going to, quote, unquote, take care of business. And so from that perspective, we don't think you need a material clarity. We just think that you need and we're likely to see just at the edges, the very, very extreme scenarios becoming less possible, i.e. we get some sort of view that there's going to be negotiation. And that to us, combined with, you know, we don't see a recession here.

16:51Our view is for 1.7 percent growth this year. And the market can deal with inflation in the high twos. 3 percent is a breakpoint. 3 percent to us if it's going to be over that. You know, the S word, stagflation, it certainly becomes a possibility. But we would argue that the market's already pricing it. So how important is this jobs number on Friday? Because that's the final piece, potentially, of the stagflation equation. It's really important, not just from what the number is. And, you know, in the parlance of Wall Street, what's interesting is the whisper number is 100 and the official number is 140.

17:30So there's wiggle room there. A five digit number is likely going to be problematic. It's also how the administration between now and Friday spins all of this. You know, if it is something where we are committed to, you know, reconstructing the U.S. economy, we understand there's pain, we know there's going to be more pain, that's not going to be the message that the market's going to want to hear, almost regardless of what the number is. But as I said, I think there's likely to be nuance in the message. So where do you think the Fed comes out on, you know, the dual mandate? If we start to see unemployment really pick up and we start to see inflation, do they do nothing?

18:15What do they do? So it's our view that Jay Powell is likely to be replaced next year. I think that's kind of obvious to most observers. and that when he thinks about his historical legacy, he rescued us from the pandemic by doing a lot. And then he raised rates and didn't destroy the economy in the doing that. And you put it all together. His legacy is tied up in keeping the soft landing going and passing it on to whoever is the next person. So from that perspective, we really don't see a world where the Fed is going to hike. And if you think about how the market has responded the last couple of years, if they don't cut, it'll be a function of the fact that the economy is judged as being OK enough to do so.

19:08Just quickly, you do recommend to clients to accumulate stocks right now. So which sectors have priced in peak uncertainty and which have not? I mean, we were talking about defensive sectors like a Walmart. That's not pricing in. Well, I guess it is pricing in uncertainty in terms of multiple expansion. But how about the others? So so what's interesting about today is that everyone basically moved their sectors in the direction of how the entire quarter was going. So you saw, you know, consumer staples outperform. You saw health care very strong. In our view, those are probably the places where defense has been hiding, where, again, all you need is a little less uncertainty.

19:49We think you go back to the prior bull market winners in general. Technology, communication services, discretionary. Julian, thank you. Good to see you. Thank you. Julian Emanuel, Evercore ISI. That's your fateful eight, Dan. Yeah, I mean, listen, it was my view. I don't know if you guys remember this. I kept on saying Qs and 2s. This is back in 2022 when people would ask, what do you buy? And people didn't think that the prior leadership was going to do the latest leadership. My view was like, you've got to take them on the way out. They're the only ones who could actually really drive it. And then the 2s was like two years, right?

20:18So if the Fed was going to lower interest rates eventually after raising, that's probably still the case. And that's the only way, in my opinion, you get back to prior highs if you do have the fateful eight participating. Because none of those other sectors, it's not financials, it's not energy, it's not a whole host of other things that even combined can do that. And I just want to make one point, listening to Julian and Steve, and they all make a lot of great points. Go back to 2018. The Fed was raising interest rates. And then all of a sudden we had this trade war kick in. And then all of a sudden we did have a global growth scare.

20:48The S &P 500 sold off 20 % in Q4 of that year. And what did the Fed do? They had to lower interest rates. And we got all that back in 2019. But I guess the question you have to ask yourself is if the Fed were starting to raise rates or lower rates, excuse me, under the same exact circumstances that exist right now, I don't think it does the thing that a lot of folks think it's going to do for the economy and thus the markets like it did in 2019. If you look at everything from staples to even XLV or health care, those charts, those relative underperformance charts to the S &P look a lot even like those international mega stocks.

21:21I mean, in other words, you had multiple years. What are those? That would be make international great again. Of course, everybody knows that. But I just I think be careful about rushing into staples here because I think the valuations here aren't terribly interesting either. Coming up, a core we've crushed. The stock tumbling well below its IPO price in its second day of trading. Why shares are off to a rocky start and what it says about the AI trade next and later. Going for gold, the precious metal just notching its best month since August 2011. But can bullion's bull run continue? We'll debate that straight ahead.

21:51More Fast Money in two.

21:55This is Fast Money with Melissa Lee right here on CNBC.

Read the full transcript

22:09Welcome back to Fast Money. AI cloud provider CoreWeave dropping more than 7 % on its second day of trading. The stock going public on Friday at$40 a share. DA David's in the first firm to start coverage of the NVIDIA-backed stock, issuing a hold rating and a price target of$36, which is lowered from$47. CNBC's Christina Parts and Elvis has got more on this. It was a pretty damning note, I thought. Yes, it was a damning note. And I'll start with the most damning part of it. Calling NVIDIA or saying that CoreWeave is being used as a special purpose vehicle for NVIDIA. So what that means is literally just off the books.

22:38NVIDIA doesn't have to take any of the risk with building out the data center infrastructure. They said also that OpenAI has a similar structure. And the reason they're saying that is because both OpenAI and NVIDIA invested in CoreWeb for a percentage. So they're now, NVIDIA is about 5%. OpenAI is about 1.6 % stakeholder. And then they also become customers. So it's really a circular relationship. And so that's probably the most damning part of that report. And then just other ones is the depreciation of data centers really removed from COG, so that inflated the gross margins up to 74 percent, when really it should be much lower.

23:16You know, it was at 25 percent. That's what they're representing. And then the debt level,$12 billion of debt with high interest at 10 to 12 percent, free cash flow, negative, burn through. So those are a lot of negatives. There are some other reports, some that were a little bit more positive, saying it's really hard to put out this infrastructure and maintain it. And Corey is a first mover in that sense. And they have contracts, multi-year contracts with some big names who have done due diligence. But those other five factors I mentioned are a major concern. Yeah. I mean, what they're talking about is the accounting part is really an issue.

23:50I mean, taking depreciation out of cost of goods sold to inflate the margins. I mean, that's... Well, depreciation isn't in the cost of goods sold. It shouldn't be in the cost of goods sold, right? So you can do that. And then what happens is, let's say three years down the road, you've got to sell all those. Or you just need to mark them to market. You're going to have a big non-cash charge. But in the prior three years, the gross margin will have been whatever it will have been. So depreciation. The bigger issue, though, is the depreciation at six years is way too long. Because these are all hopper chips.

24:27And they're still waiting for Blackwell. And then Rubin's coming. That's what it allows them to do. But all the hyperscalers are going to have to adjust that down. Amazon has already done that. I know Chris has been reporting on that. It's just math. And it's fugazi. Would we be asking these questions? I mean, I'm just going to assume that there's nothing wrong with the accounting because the companies we're talking about. But would we be asking these questions in the hypotheticals if there wasn't concern about AI compute capacity being built out to nowhere? In other words, this is about building it before they get here.

24:54And so, yeah, it seems like it's a good idea. But when there's debt component to it and you're just building capacity when we don't know what demand actually is, isn't that really the problem? Yeah, that is. And they would be at the one of the first ones to fail. But to your point, Dan, you brought up just Corey, the infrastructure build out that is concerning. The CEO over here talked about depreciation. He stopped me and he almost got angry that we keep bringing it up. And he said, no, there's other purposes for these GPU clusters. and it may not be as popular two years from now, but they're not going to be completely useless down the line.

25:29So he tried to, I guess, correct me in reporting for that. The other thing is, why aren't we questioning then every single other hyperscaler that is building out infrastructure and spending millions and billions of dollars at the same clip as CoreWeave for their products to become obsolete in just a few years too, no? So isn't it the same argument that could be applied to all of them? Yeah, but I just think it's going to be more important workloads, inference, that's going to be done by the major hyperscalers. And I think they're offloading some of their other workloads. And then when you hear the major Amazon, Microsoft, and Google talk about it, they're going to be upgrading to Blackwell and Rubin because, you know, and Jensen just told us this at GTC two weeks ago.

26:04It's going to be 100x compute. You can't do that on Hopper. You need the next generation to get the speed performance upgrades and the like here. So to me, it's just they're telling a story that just doesn't match up particularly well. And you look at a company like this with a$17 billion market cap and they have$12 billion in debt. and their service on that debt is a billion dollars, and they just raised a billion and a half dollars in cash, and they did$2 billion in revenue last year, and it's expected to be$4 billion to$8 billion. I think the debt's the issue and the reliability on really your parent or your, I'm not going to say insider, it's a naughty word, I guess, but the person that's really the reason for your being.

26:43And that, to me, if you didn't have the debt issue, I think people could live with it. All right, here's some other math, okay? So NVIDIA has now invested, what,$350 million in this company. They have bought 250 ,000 Hopper GPUs, probably at an average price of$35 ,000 or something. This is a great trade for NVIDIA, right? If you think about it, they're one of NVIDIA's biggest customers at like 7 % or 8 % or something like that. So it's, you know, what did the analysts say? A special purpose vehicle or something like that? There's some goofy stuff going on here. It's that simple. Wow. Wow. and everyone's like, what?

27:18No, I mean, this whole issue, I mean, to your point about the hyperscalers building out, their whole business doesn't revolve around leasing those data centers, right? Their business model is something else that use a data center in order to create a product that they can then use either for, I mean, in Meta's case, and sell the product. Right, right. Also, the balance sheet of the hyperscalers is, you know. Fast. Extraordinary. Yes, right. Perfect. So I'm wondering, I don't know the answer to this. Do some of these, this debt comes from obligations that they've agreed to build out data centers?

27:51Correct. So OpenAI, for example, that$12 billion deal, they still have to build out now. Right. So as they go along and meet these milestones, they pay off the debt. Correct. So are they doing any spec building? Because if they have these Microsoft and OpenAI, whoever else, you know, contracts. IBM, yeah. Right. Then, OK, so those should be money good contracts if they fulfill their obligations. But are they going out and building spec ones? I didn't get that sent. I don't know. Without a committed customer, in other words. Yes, that's what I mean. Oh, because you saw the question mark on my face.

28:21I was like, what do you mean by that? No, I don't think so. I think it really has to be contingent on they only build out once they receive a contract. So then if the contracts stop coming, then where does the build out go from there? And one last point, though, you bring up hyperscalers and all that, and their focus on infrastructure is different. Well, NVIDIA then. It's not a hyperscaler, but what's stopping them from entering that space and becoming a competitor? So right now they're an investor, a supplier, and a customer. And eventually they could be a competitor as well, right, because they have the DGX cloud.

28:48They have all the infrastructure. Well, then it makes you wonder why they have Corweave, why they want to offload that. Let them test it out first, right? Let them figure it out and then maybe go from there. All right. Christina, thanks. Christina Parts Nevelis. I just know Sandy just said we've got to go. Oh, yeah, Doug, we do. But real quick, the optics are out. Listen, just in terms of the broader market, the optics were not good. Dan mentioned it. Insider selling ahead of the IPO was not a good look. taking it down from what, I think 39 million shares or 40 million shares to 27 and a half million shares or something.

29:17That was not a good look. Reducing the price, closing at the IPO price, not a good look. And at 11 a.m. when the CEO said on one of the networks that if but for, you know, but for NVIDIA, we weren't going to get this thing priced. That's not a good, none of this optics around it were good, which I think is not good for the broader market. Yeah. A lot more fast. We did it come. Here's what's coming up next. Worrying prospect for pharma's docs, why the FDA's top vaccine doc is leaving the agency, and the ripple effects it could have throughout the healthcare sector. Plus, all that glitters is gold, the precious metal at all-time highs, and taking miners along for the ride.

29:57How to play the surge next. You're watching Fast Money, live from the NASDAQ market site in Times Square. We're back right after this.

30:13Welcome back to Fast Money. Stocks rebounding from their worst levels to finish mixed, with markets still jittery ahead of tariff announcements expected this week. The Dow gaining over 400 points. The S &P rising half a percent, while the Nasdaq fell about a tenth of a percent for its fourth straight down day. It had been down more than 2.7 percent at its lows. Gold, meantime, continuing its climb, settling at a fresh all-time high. The precious metal closing out its best quarter since 1986. Meanwhile, Newsmax making a splash on its first trading day shares of the conservative news outlet, soaring more than 700 percent, triggering a number of trading halter volatility during the session.

30:48And PVH on the move after our share surging on a top and bottom line beat. That conference call set for tomorrow before the market open. Guy, I've got to go to you on gold here. Well, go to Tim, too, because the story continues to work. It seemingly in every environment that we can come up with, gold is going moving to the upside. And the sell-offs, which you had a few of, have become shorter and shorter in duration. And there's a need for gold. By the way, I saw a headline earlier today that the Bundesbank, Germany, is actually concerned about some of the gold they still have left here in the United States.

31:17So the repatriation of gold is going to be the next story. I think the next catalyst to the upside. Coming up, a shot across the bow at the FDA as the agency's top vaccine doctor resigns. We'll take a look at the potential impact on biopharma stocks, what it can mean for public health and the future of drug development. Straight ahead.

31:44Welcome back to Fast Money. The biotech ETF XBI dropping as much as 6 % today after the abrupt resignation of the FDA's top vaccine official. Peter Marks stepped down on Friday in protest of HHS Secretary RFK Jr.'s skepticism of vaccines. Among the biggest losers today, BioNTech, Novavax, Moderna, which hit their lowest levels in over five years. For more NBC News and MSNBC medical contributor, Dr. Kavita Patel joins us now. She was also the former White House policy director under the Obama administration. Dr. Patel, always great to have you with us. The obvious candidates of vaccine makers have had a roller coaster ride since RFK's name was thrown into the ring.

32:22But Dr. Marks also oversaw gene therapies and rare diseases. How do you see this impacting sort of the pipeline that's already at the FDA and also the drug discovery process in these areas? Yeah, Melissa, it's concerning. Look, Peter Marks himself had really kind of overruled other FDA advisors with Sereptus Duchenne muscular dystrophy drugs. So this is an example where I think the leader, Peter Marks, set an example of where we needed to kind of evolve with some of these more novel therapies, namely cell and gene therapies. This is also a small step. This is a center that has 1 ,300 staff inside of a Food and Drug Administration, and these are highly specialized staff.

33:00So you can imagine, it's not just Peter. There are other kind of resignations and other people who, because of Peter's departure, also do not see a good future for themselves at the agency, and they're trying to get out as well. You can imagine that that brain drain in the immediacy is not going to result in anything. There are already kind of drugs in the pipeline for accelerated approvals, for follow-ons. However, if you're coming in and you're a Cavaletto or somebody with some novel therapies, then this is very concerning. And I'm more concerned, Melissa, that even beyond the Trump administration, we know it's a one-term administration so far, beyond this, it's going to be hard for the agency to repair this.

33:36There are also other ripple effects out there in terms of the impact of RFK Jr. when it comes to funding withdrawal. For instance, we're reading in publications like The Hill about, you know, universities elsewhere in the world, courting scientists in the U.S. who are seeking scientific asylum, basically, the freedom to research scientific issues, medical issues, without concern for retribution or pulling of funding. This could mean generations of scientists lost here in the United States. Yeah. Well, I've got a postdoc. I teach a class at Stanford. I've got a postdoc. You just had a robust conversation about AI, the future of AI and kind of where that technology is going, there's no better use case for where AI could have promised than in drug discovery and some of the things that are happening.

34:21I have several postdocs who have had exactly these offers from countries, China, India, other countries have actively been reached out to and said, do you want a more stable environment? Do you want to have security after you finish your doctoral training? And it's really hard to kind of argue with that. And so this isn't just something in theory, we're seeing this playing out every day. And you probably just saw the recent headline in the Wall Street Journal about Harvard University potentially being a target. So this is going to have, I think, even I worry even more, Melissa, about that situation with the kind of uncertainty of funding, as well as kind of uncertain immigration status, and the ability to kind of hold jobs in the United States for what I think we've been doing very well for decades now, which is biotechnology and kind of innovation writ large.

35:08How potentially problematic is this for people that want to get into the field. I guess my question is, how many years can this set back the industry, if you were to guess? Yeah. Well, I don't have to guess too much, unfortunately. I worked in the early part of the century, in the 2000s, I worked on a lot of these FDA reforms because we saw so many setbacks from problematic FDA staffing, problems with NIH grant dollars in the 80s and 90s. A lot of that was really budgetary, so it wasn't what we're seeing today. But it took us the early part of the 2000s up to the kind of Cures Act, even through the first Trump administration.

35:44It took us a good 20 years to really right the ship, to give the FDA, the NIH, and a lot of these agencies the resources they need, because it comes down to dollars. And it's a zero-sum game. If you're going to put dollars somewhere, you've got to get it from somewhere else. So it did take us several decades to put in user fees, to put in device fees, to do a lot of this innovation. I worry it's going to take us just as much time. And I don't think legislators understand that. I think we've all seen the power of a good FDA when we can get accelerated approvals, cancer therapies that are coming at what seems like a clip.

36:15But we haven't, we don't remember what probably several of us on this panel remember several decades ago about how long it took to get some of these novel therapies in the United States. But I worry that's what we're going to get to. And we'll probably see that disruption over the next three to five years. Dr. Pease, Tim, so that's where I wanted to get to. How quickly can, you know, talk about the process for funding and cutting of funding and at least help take the other side of the argument why this is happening. Is this totally ideological? Is this fiscal? Help us understand how and why this is at least a movement that's happening.

36:49Yeah, I'll start there. I think that there is truth like all things in, Tim, like the movement to, you know, why should 80 cents on an NIH dollar pay for buildings and overhead? Why shouldn't it be applied directly to the kind of research that we intended for that grant to fund. I think that's where some of that kernel starts. And that is certainly true. Indirect costs, by the way, there's actually a complex formula for this. So it's not as if universities are trying to cheat the NIH, but that's basis number one. I think the second basis to your point around the ideology is this abrupt cancellation.

37:21The NIH has really kind of put out there in a spreadsheet publicly available, a very clear kind of listing of cancellations that are kind of quote, not in line with the priority of this administration, not just vaccines, but a lot of other issues related to research around sexual activity, other diseases, communicable diseases, those kinds of changes and wholesale eliminations, that is really going to set back the research community, because that's what we've been doing for decades is putting forward advances in these areas. An advance in HIV advances cancer. An advance in COVID vaccines advances cancer.

37:57So these are not just kind of in isolation. So I don't think we'll see an immediate effect. We've got an FDA that's working and they've got things in the pipeline and the private sector is kind of pairing with that. But three to five years from now, that will that will be hard to match. Dr. Patel, always great to see you. Thank you. Thanks. Thank you. Kavita Patel. Coming up, a search slip up for Google. One analyst sounding the alarm on the company's competitive edge in AI search. We'll bring you the details on that call next. More Fast Money right after this.

38:34Welcome back to Fast Money. Melia's research downgrading Alphabet to a whole today. The analyst Ben Reitz is airing out concerns over the tech giant's search business, saying Google's flagship search engine is at risk of going the way of Kodak. Google has lagged the broader market this year, down almost 18 percent in 2025. Basically said, is Google losing the word? There's probably a whole generation out there not Googling. they're chat GPT-ing, and so chat GPT-ing may be winning. Yeah, just not yet. I mean, like we've been talking about this. We have the perplexity CEO on, I want to say, beginning of the year, and I remember at the point in time, it's just like people are, what are these things?

39:08You know, they've been hearing about this sort of stuff, so they're still Googling for the most part. The problem that I think with Google has right now is that their models, their ability to integrate Gemini across their suite of services is just not done well, and their products are not kind of matching up particularly well against OpenAI and some of these other models out there. So This is not a thing right here and now, but it will be if they don't catch up to it. You know, this is a company that has seven properties that have over a billion, like four or five have over a couple billion. If they get this right, they're going to cannibalize that search business, but they're going to be well positioned going forward.

39:40It's just the jury's still out where they're going to get it right now. Yeah, well, the jury's still out and we also have the settlement, whatever that may be. I think he addresses it in that piece saying he doesn't think that'll be a major change. He still has a hold on it, I believe, right? I mean, it's an extraordinary property. It's not expensive by any measure, but I do feel like the rollout was bad going back a year and change ago. And I do feel like I would like more of a sense of urgency than they seem to have. You know, Ben's been on the show. He obviously thought that he just throw out Eastman Kodak.

40:11I mean, he thought about that. He covered Eastman Kodak back in the day. And the obsolescence and how quickly it became obsolete. I mean, that was a thing back in the day. Now, again, I think there's a long way to go. But for him to put that out there at this point in time, I think if nothing else, it's worth putting that little bookmark on. Well, and of all the stocks that have sold off really in the mag seven outside of semiconductors, 28 percent in 51 days. I mean, it's been shocking. Coming up, the lowdown on Live Nation, why the Trump administration is taking aim at ticket pricing, what it all means ahead of a rival company's IPO.

40:42You're watching Fast Money Live from the NASDAQ Market Sight. Back right after this.

40:54Welcome back to Fast Money. Shares of Ticketmaster Parent Live Nation dropping after hours after President Trump announced plans to sign an executive order targeting ticket scalping. The stock had been up during the regular session as rival StubHub revived plans to go public. We don't have a lot of details on this EO yet, Karen. No, we don't. I mean, this has been, you know, Live Nation has faced this many times. It's such a popular thing to go after, right? Who wants higher ticket prices? Nobody. But I think of all of them, Ticketmaster is the most transparent. This is unfortunate timing for StubHub.

41:26But we've seen them fight this before in the business. Yeah, but for Ticketmaster, it's very different than StubHub. 80 % of their sales are primary. All right. So this is really here. It's the secondary Vivid, StubHub. There's a few others, SeatGeek. The other thing I'll just add to this, I mean, when you think about Ticketmaster, you think of their positioning, there also is this dynamic pricing on the primary that people got really pissed off, the Taylor Swift stuff. You know, so like if there's greater demand, the tickets could go up from$200 to like$900 or something like that. So I wonder if they're going to take a crack at that as a related ticket master.

41:59I mean, Mike Damone did not want to be known as a scalper when he was getting Jefferson, Earth, Wind and Fire tickets. Cheap trick as well. Cheap trick, yeah. The genius of cheap trick. He didn't want to be known as a scalper, but he was. Final trades.

42:26Final trade time, Tim. Five-year highs in Altria, M.O. I think it goes higher. Karen. Yes. Well, I'm always along, but I do have some hedges on, like short HYG. Dan Nathan. Yeah, the big pharma XLV looks okay. One night we had a big crowd at the beginning of the show. Dr. Patel came in. Yeah. A lot of movement. Dynamic. You know, ExxonMobil's had a nice little run, Melissa Lee. I think our viewers should take a close look at XOM. All right. Thanks for watching Fast Money. See you back here tomorrow at 5 for more Fast Mad Money with Jim Cramer starts right now.

43:39Thank you.

From the publisher

The S&P and Dow eked out a gain on Monday but all indexes closed the quarter with significant losses. This as investors await the onset of President Trump’s tariffs and the announcement of reciprocal levies. Plus the FDA’s vaccine head abruptly resigned over the weekend. What that means for drug development in the U.S. 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Markets on edge as tariff deadline looms & the future of vaccine development in the FDA 3/31/25CNBC's "Fast Money" · 44 min
Listen in VO